Background/Aims
The novel infectious disease COVID-19 is associated with a wide spectrum of clinical severity amongst the general population. Patients with autoimmune rheumatic diseases (ARD) are more likely to experience serious COVID-19 related events, although risk factors for such outcomes have yet to be established. In particular, the risk profiles of specific ARD therapies are unknown.

Methods
A Scottish wide registry was rapidly developed in March 2020. Clinical characteristics and outcomes of infected cases were collated across all Scottish health boards, leveraging the Scottish Systemic Vasculitis Network and Scottish Society for Rheumatology. Eligible patients included any adult ARD patients with a confirmed (clinically or PCR) diagnosis of COVID-19. Simple descriptive statistics were employed to evaluate associations between ARD therapies and a serious COVID-19 disease outcome, as defined by a requirement of invasive or non-invasive ventilation, and/or death.

Results
A total of 69 patients (59% female; mean age 65.6, SD 15.5) were recruited to the registry, 92% of which required hospitalisation. Cases were most commonly diagnosed with rheumatoid arthritis (n = 32, 46.4%) followed by spondyloarthritis (n = 19, 27.5%) and systemic vasculitis (n = 9, 13.0%). Anti-TNF therapy (n = 8, 11.6%) and methotrexate (n = 31, 44.9%) were the commonest biologic and conventional disease modifying drug (bDMARD and csDMARD) used respectively. N = 20 (29%) received background corticosteroid therapy (5.9% prednisolone >5mg, 13% prednisolone ≤5mg). A severe outcome was observed in n = 25(31.9%); n = 11 required assisted ventilation and n = 19 died. With the exception of Leflunomide, conventional and biologic DMARDs did not appear to confer a higher risk for severe outcome (table 1). Of note, anti-TNF therapy was associated with a non-serious outcome (p = 0.04) and prednisolone ≤5 mg with a serious outcome (p = 0.08).

ORAL ABSTRACT PRESENTATIONS
Rheumatology, NHS Grampian, Aberdeen, UNITED KINGDOM, 2Department of Rheumatology, NHS Greater Glasgow & Clyde, Glasgow, UNITED KINGDOM, 3Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UNITED KINGDOM, 4Renal Unit, NHS Grampian, Aberdeen, UNITED KINGDOM, 5Department of Rheumatology, NHS Lanarkshire, Lanarkshire, UNITED KINGDOM, 6Department of Rheumatology, NHS Dumfries and Galloway, Dumfries and Gal, UNITED KINGDOM, 7Department of Rheumatology, NHS Borders, Borders, UNITED KINGDOM, 8Department of Rheumatology, NHS Highlands, Inverness, UNITED KINGDOM, 9Department of Rheumatology, NHS Lothian, Edinburgh, UNITED KINGDOM, 10Department of Rheumatology, NHS Forth Valley, Forth Valley, UNITED KINGDOM, 11Department of Rheumatology, NHS Ayrshire and Arran, Ayrshire, UNITED KINGDOM, 12Department of Rheumatology, NHS Fife, Fife, UNITED KINGDOM, 13Department of Rheumatology, NHS Tayside, Dundee, UNITED KINGDOM

Background/Aims
The novel infectious disease COVID-19 is associated with a wide spectrum of clinical severity amongst the general population. Patients with autoimmune rheumatic diseases (ARD) are more likely to experience serious COVID-19 related events, although risk factors for such outcomes have yet to be established. In particular, the risk profiles of specific ARD therapies are unknown.

Methods
A Scottish wide registry was rapidly developed in March 2020. Clinical characteristics and outcomes of infected cases were collated across all Scottish health boards, leveraging the Scottish Systemic Vasculitis Network and Scottish Society for Rheumatology. Eligible patients included any adult ARD patients with a confirmed (clinically or PCR) diagnosis of COVID-19. Simple descriptive statistics were employed to evaluate associations between ARD therapies and a serious COVID-19 disease outcome, as defined by a requirement of invasive or non-invasive ventilation, and/or death.

Results
A total of 69 patients (59% female; mean age 65.6, SD 15.5) were recruited to the registry, 92% of which required hospitalisation. Cases were most commonly diagnosed with rheumatoid arthritis (n = 32, 46.4%) followed by spondyloarthritis (n = 19, 27.5%) and systemic vasculitis (n = 9, 13.0%). Anti-TNF therapy (n = 8, 11.6%) and methotrexate (n = 31, 44.9%) were the commonest biologic and conventional disease modifying drug (bDMARD and csDMARD) used respectively. N = 20 (29%) received background corticosteroid therapy (5.9% prednisolone >5mg, 13% prednisolone ≤5mg). A severe outcome was observed in n = 25(31.9%); n = 11 required assisted ventilation and n = 19 died. With the exception of Leflunomide, conventional and biologic DMARDs did not appear to confer a higher risk for severe outcome (table 1). Of note, anti-TNF therapy was associated with a non-serious outcome (p = 0.04) and prednisolone ≤5 mg with a serious outcome (p = 0.08).

030 TABLE 1: Demographics, clinical characteristics and outcomes

| Critical outcome | Non-critical outcome | Total | p value |
|------------------|----------------------|-------|---------|
| n = 25           | n = 44               | 69    | 0.09    |
| Age (years) (mean ± SD) | 69 ± 12.9 | 63.4 ± 16.5 | 65.6 ± 15.5 | 0.09 |
| Female, n (%)    | 14 (56)             | 27 (61.4) | 41 (59.4) | 0.66 |
| Rheumatological Treatment, n (%) | | | | |
| bDMARD/ tsDMARD, n (%) | | | | |
| Anti-TNF         | 0 (0)           | 8 (18.2) | 8 (11.6) | 0.04 |
| Rituximab        | 3 (12)          | 3 (6.8)  | 6 (8.7)  | 0.66 |
| Secukinumab      | 0 (0)           | 2 (4.5)  | 2 (2.9)  | 0.53 |
| Infliximab       | 0 (0)           | 1 (2.3)  | 1 (1.4)  | 1     |
| JAK-inhibitors   | 2 (8)           | 1 (2.3)  | 3 (4.3)  | 0.30 |
| Anakinra         | 0 (0)           | 1 (2.3)  | 1 (1.4)  | 1     |
| csDMARD, n (%)   |                |         |         |       |
| Methotrexate     | 11 (44)         | 20 (45.5) | 31 (44.9) | 0.91 |
| Sulfasalazine    | 5 (20)          | 7 (15.9) | 12 (17.4) | 0.66 |
| Leflunomide      | 3 (12)          | 0 (0.0)  | 3 (4.3)  | 0.04 |
| Mycophenolate    | 1 (4)           | 2 (4.5)  | 3 (4.3)  | 1     |
| Azathioprine     | 0 (0)           | 1 (2.3)  | 1 (1.4)  | 1     |
| Hydroxychloroquine | 5 (20)      | 6 (13.6) | 11 (15.9) | 0.49 |
| Prednisolone, n (%) | 10 (40)   | 10 (22.7) | 20 (29) | 0.13 |
| Prednisolone ≤5mg | 3 (12)       | 6 (13.6) | 9 (13)  | 1     |
| Prednisolone >5mg | 7 (28)        | 4 (9.1)  | 11 (15.9) | 0.08 |
| Not on csDMARD/ tsDMARD, n (%) | 5 (20) | 10 (22.7) | 15 (21.7) | 0.79 |

*Critical outcome refers to ventilation requirement and/or death.
**P-values were derived from simple descriptive statistics, t-test, fisher exact test or chi-squared test as appropriate.

REGISTERS
030 VARIATION IN IMMUNOSUPPRESSANT IMPACT ON SEVERE COVID-19 OUTCOME: PRELIMINARY RESULTS FROM THE COVID-19 SCOTTISH REGISTRY OF AUTOIMMUNE RHEUMATIC DISEASES (SCAR-19)
Maira Karabasayi1,2, James Brock1, Matthew Rutherford2, Gillian Fordyce2, Nick Fluck2, Sally Kardash2, Lucy Moran2, Ruth Richmond2, Adrian Tan8, Jan Sznajd8, Stewart Lambie8, Mohmmed Khalid1,2, Sara Else1, Carol A. Davies1, Margaret Duncan1, John McIntyre1, Sean Duncan1, Sean Murphy5, Fuad Hasan1 and Neil Basu1
1Aberdeen Centre for Arthritis & Musculoskeletal Health, University of Aberdeen, Aberdeen, UNITED KINGDOM, 2Department of
ORAL ABSTRACT PRESENTATIONS

Conclusion
Preliminary data from this Scotland-wide ARD COVID-19 registry evidences variation in the impact of standard ARD therapies on the severity of COVID-19 outcome. In general, background csDMARD and bDMARD use does not appear to be a risk factor for severe outcomes. However, anti-TNF therapy may confer a favourable outcome, while leflunomide and corticosteroids may have the opposite effect. Rheumatologists should be aware of these possible risk factors and continue to contribute to registries to help establish whether these putative signals are clinically relevant.

Disclosure
M. Karabayas: None. J. Brock: None. M. Rutherford: None. G. Fordyce: None. N. Fluck: None. S. Kardash: None. L. Moran: None. R. Richmond: None. A. Tan: None. J. Sznajd: None. S. Lambie: None. M. Khalid: None. S. Else: None. C.A. Davies: None. M. Duncan: None. J. McLaren: None. S. Duncan: None. S. Murphy: None. F. Hasan: None. N. Basu: None.